PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.18%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-3.63%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.36%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-11.36%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.69%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-9.76%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.18%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.22%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
1.20%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-38.66%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-73.49%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
19.20%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
47.21%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
60.39%
3Y revenue/share CAGR similar to AVGO's 60.90%. Walter Schloss would assume both companies experience comparable short-term cycles.
839.85%
10Y OCF/share CAGR above 1.5x AVGO's 441.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
422.47%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
199.68%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
243.23%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
183.91%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
427.26%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
154.02%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-3.52%
Negative 5Y equity/share growth while AVGO is at 147.32%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
10.46%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
43.45%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
44.81%
5Y dividend/share CAGR at 50-75% of AVGO's 71.80%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
36.80%
3Y dividend/share CAGR similar to AVGO's 38.29%. Walter Schloss finds parallel short-term dividend strategies for both companies.
9.10%
AR growth well above AVGO's 14.59%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.12%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-6.80%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.73%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-51.89%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.60%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-0.94%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.